Synergy CHC Gets Nasdaq Delisting Notice After Chapter 11 Filing

What happened

Synergy CHC Corp., a Nevada-incorporated company whose common stock trades under the ticker SNYR on the Nasdaq Stock Market, received a letter on September 11, 2026 from the staff of Nasdaq's Listing Qualifications Department stating that its securities will be delisted, according to an 8-K filed with the Securities and Exchange Commission on September 16, 2026.

The company disclosed in the same filing that it and certain subsidiaries filed voluntary petitions for relief under chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Columbia on September 4, 2026. That earlier filing was described in the 8-K as previously reported.

Nasdaq's letter states that trading of Synergy's common stock will be suspended at the opening of business on September 18, 2026, and that a Form 25-NSE will be filed with the SEC to remove the securities from listing on Nasdaq. Synergy said it does not presently intend to appeal the determination.

Why Nasdaq cited

According to the filing, Nasdaq's staff based its determination on three factors: the bankruptcy filing and associated public interest concerns it raises; concerns about the residual equity interest of existing listed securities holders; and concerns about the company's ability to sustain compliance with all requirements for continued listing.

The 8-K cites Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1 as the basis for the delisting. The filing does not add further explanation beyond the three factors listed.

The stock move

Same-day price data show Synergy shares closed at $0.2744, up 234.63% from the prior close of $0.082, on volume of 1,078,260,219 shares against an average volume of 12,889,748. Volume was roughly 83.65 times the average.

The sources do not explain what drove the price and volume move. The 8-K describes a delisting notice and a plan to suspend trading, and does not address the trading session.

What this means

An 8-K is a current report that a US public company must file with the SEC when certain material events occur, generally within four business days. Item 3.01, which this filing checks, specifically covers a notice of delisting or a failure to satisfy a continued listing rule — so the form type itself signals that the news is about the company's place on an exchange rather than its operating results.

Nasdaq's Rule 5101 gives the exchange broad discretion to deny continued listing where it believes doing so is in the public interest, and Rule 5110(b) and IM-5101-1 govern the process for removing a security from listing. A delisting notice is the exchange's written statement that it has decided to stop listing the stock; the company can typically appeal to a hearings panel, but here the 8-K states Synergy does not presently intend to.

The Form 25-NSE referenced in the letter is the actual mechanism for removal. A Form 25 is how a security comes off an exchange listing; either the company or the exchange can file one. The '-NSE' suffix indicates Nasdaq is the filer. Once it takes effect, the stock no longer trades on Nasdaq. A Form 25 dealing with debt securities such as notes reaching maturity is routine, because the bond is simply being repaid on schedule; a Form 25 for common stock is a different matter, since it ends the company's listing on that exchange.

Synergy CHC Corp. is listed by the SEC under the industry classification Medicinal Chemicals & Botanical Products, with its principal executive offices at 770 Roosevelt Trail, Suite 8 #1016, N. Windham, Maine. The company's common stock carries a par value of $0.00001 per share — par value is a nominal figure set in the corporate charter, not the market price.

The mention of 'residual equity interest' refers to what is left for existing shareholders once creditors are paid in a bankruptcy. Chapter 11 is a court-supervised reorganization, and the filing indicates Nasdaq flagged concern about whether any value remains for holders of the common stock. The 8-K does not state what will happen to the shares after the suspension, and the company has not said whether it intends them to trade elsewhere.